2006•Schizophrenia ResearchRequires access

A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA)

Rajiv Tandon, Ronald N. Marcus, Elyse G. Stock, Linda C. Riera, Dusan Kostic, Miranda Pans, Robert D. McQuade, Margaretta Nyilas, Taro Iwamoto, DAVID T. CRANDALL

Open publisher page 108 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 108 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Aripiprazole, Schizoaffective disorder, Schizophrenia (object-oriented programming), Medicine, Clinical endpoint, Adverse effect, Internal medicine, Psychiatry

Back to paper search Browse research topics Original source

A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA) — Research Paper | ScholarLens